PE20000335A1 - Apoptosis auto-regulada de celulas inflamatorias mediante terapia genica - Google Patents
Apoptosis auto-regulada de celulas inflamatorias mediante terapia genicaInfo
- Publication number
- PE20000335A1 PE20000335A1 PE1999000161A PE00016199A PE20000335A1 PE 20000335 A1 PE20000335 A1 PE 20000335A1 PE 1999000161 A PE1999000161 A PE 1999000161A PE 00016199 A PE00016199 A PE 00016199A PE 20000335 A1 PE20000335 A1 PE 20000335A1
- Authority
- PE
- Peru
- Prior art keywords
- nucleic acid
- tnfo
- promoter
- apoptosis
- pcr
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 230000007820 inflammatory cell apoptotic process Effects 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 102000001398 Granzyme Human genes 0.000 abstract 1
- 108060005986 Granzyme Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
SE REFIERE A LA INDUCCION DE APOPTOSIS EN CELULAS INFLAMATORIAS AL INTRODUCIR EN ESAS CELULAS UN GEN QUE INDUCE LA APOPTOSIS Y A UNA MOLECULA DE ACIDO NUCLEICO QUIMERICO QUE COMPRENDE UNA REGION DE REFORZADOR DE 123 o 190 BASES o 114 o 169 BASES DE ACIDO NUCLEICO O COMBINACIONES DE LOS MISMOS; Y QUE ESTA UNIDO A UN PROMOTOR DE TNFO DE 1178 o 1096 o 139 BASES DE ACIDO NUCLEICO, EL QUE ESTA UNIDO A LA VEZ A UNA SECUENCIA QUE CODIFICA LA PROTEINA GRANZYME B; LA QUE ESTA UNIDA A LA VEZ A UNA SECUENCIA DE ACIDO NUCLEICO 3`UTR. TAMBIEN SE REFIERE A UN METODO PARA LA PREPARACION QUE COMPRENDE AMPLIFICAR LA CADENA ADN QUE COMPRENDE UN PROMOTOR DE TNFO MEDIANTE UNA REACCION EN CADENA DE POLIMERASA UTILIZANDO CEBADORES; CLONAR EL ACIDO NUCLEICO AMPLIFICADO POR PCR CON ACIDO NUCLEICO INFORMADOR PARA PRODUCIR UNA CONSTRUCCION; SOMETER A ENSAYO LAS CONSTRUCCIONES OBTENIDAS, SELECCIONAR EL PROMOTOR DE TNFO RESPONSABLE DE LA INDUCCION; AMPLIFICAR POR PCR REGIONES DEL PROMOTOR DE TNFO QUE REFUERZAN LA EXPRESION DEL INFORMADOR PARA OBTENER UN REFORZADOR Y LIGARLO MAS ARRIBA DEL PROMOTOR; INSERTAR UNA COPIA DE ACIDO NUCLEICO INDUCTORA DE APOPTOSIS DESPUES DEL PROMOTOR DE TNFO REEMPLAZANDO EL INFORMADOR POR LAS CONSTRUCCIONES DE DELECION DE ACIDO NUCLEICO INDUCTOR DE APOPTOSIS; AMPLIFICAR POR PCR TNFO-3'UTR Y LIGARLA AL INDUCTOR DE APOPTOSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7631698P | 1998-02-27 | 1998-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000335A1 true PE20000335A1 (es) | 2000-04-26 |
Family
ID=22131220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000161A PE20000335A1 (es) | 1998-02-27 | 1999-02-25 | Apoptosis auto-regulada de celulas inflamatorias mediante terapia genica |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6537784B1 (es) |
| EP (1) | EP1056877A1 (es) |
| JP (1) | JP2002504381A (es) |
| KR (1) | KR20010086587A (es) |
| CN (1) | CN1292032A (es) |
| AR (1) | AR014661A1 (es) |
| AU (1) | AU761497B2 (es) |
| BR (1) | BR9909250A (es) |
| CA (1) | CA2321178A1 (es) |
| CO (1) | CO4820446A1 (es) |
| HU (1) | HUP0100776A3 (es) |
| IL (1) | IL137871A0 (es) |
| NZ (1) | NZ506941A (es) |
| PE (1) | PE20000335A1 (es) |
| PL (1) | PL343248A1 (es) |
| TR (1) | TR200002496T2 (es) |
| WO (1) | WO1999043840A1 (es) |
| ZA (1) | ZA991519B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039186A1 (en) * | 1997-02-28 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Self-regulated apoptosis of inflammatory cells by gene therapy |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7101977B2 (en) * | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| US6867237B1 (en) * | 2001-07-23 | 2005-03-15 | Senesco Technologies, Inc. | DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans |
| SI1537204T1 (sl) * | 2002-08-23 | 2010-06-30 | Gabriele Prof Dr Multhoff | Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah |
| WO2004028342A2 (en) * | 2002-09-25 | 2004-04-08 | Board Of Regents, The University Of Texas System | Endogenous granzyme b in human non-hematopoietic cells |
| AU2006304804B2 (en) * | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
| US20090136465A1 (en) * | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01137976A (ja) * | 1987-11-20 | 1989-05-30 | Asahi Chem Ind Co Ltd | 新規ｄｎａフラグメント |
| US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| AU684050B2 (en) * | 1992-07-13 | 1997-12-04 | Baylor College Of Medicine | Targeting somatic gene therapy to joints |
| IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
| US5744304A (en) | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| EP0861092A4 (en) * | 1995-08-30 | 2002-04-10 | Univ California | THERAPY FOR CELLULAR ACCUMULATION IN CHRONIC INFLAMMATORY DISEASES |
| ATE362369T1 (de) * | 1997-02-28 | 2007-06-15 | Boehringer Ingelheim Pharma | Selbst-regulierte apoptose von entzuendungszellen durch gentherapie |
-
1999
- 1999-01-12 CN CN99803317A patent/CN1292032A/zh active Pending
- 1999-01-12 IL IL13787199A patent/IL137871A0/xx unknown
- 1999-01-12 NZ NZ506941A patent/NZ506941A/en unknown
- 1999-01-12 WO PCT/US1999/000637 patent/WO1999043840A1/en not_active Ceased
- 1999-01-12 HU HU0100776A patent/HUP0100776A3/hu unknown
- 1999-01-12 BR BR9909250-6A patent/BR9909250A/pt not_active IP Right Cessation
- 1999-01-12 TR TR2000/02496T patent/TR200002496T2/xx unknown
- 1999-01-12 EP EP99901438A patent/EP1056877A1/en not_active Withdrawn
- 1999-01-12 KR KR1020007009326A patent/KR20010086587A/ko not_active Withdrawn
- 1999-01-12 PL PL99343248A patent/PL343248A1/xx unknown
- 1999-01-12 US US09/229,151 patent/US6537784B1/en not_active Expired - Lifetime
- 1999-01-12 AU AU21132/99A patent/AU761497B2/en not_active Ceased
- 1999-01-12 JP JP2000533579A patent/JP2002504381A/ja active Pending
- 1999-01-12 CA CA002321178A patent/CA2321178A1/en not_active Abandoned
- 1999-02-24 CO CO99011570A patent/CO4820446A1/es unknown
- 1999-02-25 ZA ZA9901519A patent/ZA991519B/xx unknown
- 1999-02-25 PE PE1999000161A patent/PE20000335A1/es not_active Application Discontinuation
- 1999-02-26 AR ARP990100832A patent/AR014661A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010086587A (ko) | 2001-09-13 |
| HUP0100776A3 (en) | 2003-08-28 |
| TR200002496T2 (tr) | 2000-11-21 |
| CA2321178A1 (en) | 1999-09-02 |
| AU2113299A (en) | 1999-09-15 |
| HUP0100776A2 (hu) | 2001-06-28 |
| BR9909250A (pt) | 2001-09-04 |
| US6537784B1 (en) | 2003-03-25 |
| AR014661A1 (es) | 2001-03-28 |
| EP1056877A1 (en) | 2000-12-06 |
| ZA991519B (en) | 1999-11-23 |
| CN1292032A (zh) | 2001-04-18 |
| WO1999043840A1 (en) | 1999-09-02 |
| AU761497B2 (en) | 2003-06-05 |
| IL137871A0 (en) | 2001-10-31 |
| CO4820446A1 (es) | 1999-07-28 |
| NZ506941A (en) | 2004-01-30 |
| JP2002504381A (ja) | 2002-02-12 |
| PL343248A1 (en) | 2001-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martemyanov et al. | Cell-free production of biologically active polypeptides: application to the synthesis of antibacterial peptide cecropin | |
| CL2020002704A1 (es) | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial | |
| CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
| Li et al. | Runx2 contributes to murine Col10a1 gene regulation through direct interaction with its cis‐enhancer | |
| PE20000335A1 (es) | Apoptosis auto-regulada de celulas inflamatorias mediante terapia genica | |
| ATE302267T1 (de) | Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert | |
| DE69835085D1 (de) | Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor | |
| ATE323510T1 (de) | Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen | |
| PE20050376A1 (es) | Anticuerpos dirigidos a m-csf | |
| DK496185D0 (da) | Autonome replikationssekvenser for gaerstammer af slaegten pichia | |
| PT695360E (pt) | Adenovirus recombinantes deficientes, para a terapia genica de tumores | |
| DK1471926T3 (da) | Sammensætninger og fremgangsmåder til terapeutisk anvendelse af en atonal-associeret sekvens | |
| US20090239219A1 (en) | Telomerase expression repressor proteins and methods of using the same | |
| Yuan et al. | Role of RNA splicing in mediating lineage-specific expression of the von Willebrand factor gene in the endothelium | |
| US20070238639A1 (en) | Telomerase expression repressor proteins and methods of using the same | |
| WO2012149566A2 (en) | Anti-hiv group i introns and a uses thereof in treating hiv infections | |
| Filippovich et al. | Cloning and functional expression of venom prothrombin activator protease from Pseudonaja textilis with whole blood procoagulant activity | |
| Kaul et al. | Isolation and characterization of human blood-coagulation factor X cDNA | |
| Choi et al. | Characterization of the 5′-flanking region of the rat gene for mitochondrial transcription factor A (Tfam) | |
| ATE534902T1 (de) | Replikationsproteinn ciz1 | |
| Noori-Zadeh et al. | Non-viral human proGDNF gene delivery to rat bone marrow stromal cells under ex vivo conditions | |
| US9926359B2 (en) | Optogenetic inhibition of overactive neuronal activity | |
| ATE313631T1 (de) | Dna polymerase lambda und ihre verwendungen | |
| ATE420975T1 (de) | Methode zur linearen nicht-selektiven amplifikation von nukleinsäuren | |
| AR032686A1 (es) | Elementos reguladores adecuados para usar en la expresion genetica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |